As Regeneron Pharmaceuticals (REGN) Stock Rose, Halsey Associates Has Lifted Position; Adelphi Capital Llp Has Lowered Its Holding in Liberty Global Plc (LBTYK) by $10.00 Million

January 18, 2018 - By Vivian Park

Halsey Associates Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 74.89% based on its latest 2017Q3 regulatory filing with the SEC. Halsey Associates Inc bought 6,458 shares as the company’s stock rose 21.24% with the market. The institutional investor held 15,081 shares of the health care company at the end of 2017Q3, valued at $6.74 million, up from 8,623 at the end of the previous reported quarter. Halsey Associates Inc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $39.63 billion market cap company. The stock decreased 0.88% or $3.3 during the last trading session, reaching $370.77. About 187,269 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since January 18, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Adelphi Capital Llp decreased its stake in Liberty Global Plc (LBTYK) by 8.44% based on its latest 2017Q3 regulatory filing with the SEC. Adelphi Capital Llp sold 312,437 shares as the company’s stock declined 17.26% while stock markets rallied. The institutional investor held 3.39 million shares of the television services company at the end of 2017Q3, valued at $110.80 million, down from 3.70M at the end of the previous reported quarter. Adelphi Capital Llp who had been investing in Liberty Global Plc for a number of months, seems to be less bullish one the $34.95B market cap company. The stock increased 0.17% or $0.06 during the last trading session, reaching $34.8. About 546,460 shares traded. Liberty Global plc (NASDAQ:LBTYK) has declined 6.78% since January 18, 2017 and is downtrending. It has underperformed by 23.48% the S&P500.

Among 31 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 17 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. had 104 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by Oppenheimer given on Thursday, August 3. The rating was initiated by Citigroup with “Buy” on Thursday, February 25. The stock has “Outperform” rating by Credit Suisse on Tuesday, December 20. The company was maintained on Thursday, September 7 by Robert W. Baird. The stock has “Buy” rating by Evercore on Wednesday, August 16. The stock has “Hold” rating by Canaccord Genuity on Wednesday, January 27. The company was initiated on Tuesday, March 15 by Gabelli. On Thursday, August 3 the stock rating was maintained by BTIG Research with “Buy”. The firm has “Neutral” rating given on Friday, December 1 by Citigroup. The company was maintained on Monday, September 11 by Credit Suisse.

Since August 7, 2017, it had 2 buys, and 8 insider sales for $78.43 million activity. VAGELOS P ROY sold $7.14M worth of stock. Landry Robert E sold 526 shares worth $248,372. $712,500 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by BROWN MICHAEL S on Thursday, October 5. The insider Sanofi bought $34.84 million.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It worsened, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Maryland-based Ithaka Gru Lc has invested 3.3% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Sectoral Asset Management Inc reported 32,917 shares. Manning & Napier Ltd Llc has 284,193 shares for 1.09% of their portfolio. New York-based Rockefeller Financial Serv Incorporated has invested 1.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Cap Planning Advisors Limited Liability Company has invested 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The New York-based Two Sigma Securities Ltd Liability Corporation has invested 0.04% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Caxton Associates Limited Partnership owns 0.01% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 600 shares. Sg Americas Securities Limited Liability Co holds 10,148 shares or 0.04% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0.07% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 17,954 shares. The Alabama-based Oakworth Capital has invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Pinebridge Invs Limited Partnership stated it has 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Tekla Capital Mgmt Lc reported 2.73% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Winslow Cap Mngmt Limited Liability Corporation holds 0% or 9 shares. Eventide Asset Limited Liability Corporation stated it has 7,500 shares. Tocqueville Asset Management Lp stated it has 10,378 shares or 0.05% of all its holdings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: